Celgene's Robert J. Hugin Becomes PhRMA Board Chairman; Ian C. Read, Kenneth C. Frazier Assume New Posts

 Celgene's Robert J. Hugin Becomes PhRMA Board Chairman; Ian C. Read, Kenneth
                         C. Frazier Assume New Posts

PR Newswire

SAN DIEGO, April 12, 2013

SAN DIEGO, April 12, 2013 /PRNewswire-USNewswire/ -- Robert J. Hugin, chairman
and CEO of Celgene Corporation, was elected chairman of the Pharmaceutical
Research and Manufacturers of America (PhRMA) today at the trade association's
annual meeting. Also elected were Ian C. Read, president and CEO of Pfizer
Inc, as chairman-elect of the PhRMA Board of Directors, and Kenneth C.
Frazier, Chairman, President and CEO of Merck & Co, Inc., as Board treasurer.

(Logo: http://photos.prnewswire.com/prnh/20091027/PHRMALOGO)

Mr. Hugin succeeds John C. Lechleiter, Ph.D., chairman, president, and CEO of
Eli Lilly and Company, as PhRMA's chairman.

"John Lechleiter's tireless leadership over the past year has helped to
reinvigorate the biopharmaceutical research sector at a time when a
challenging public policy environment threatens to put America's global
leadership in medical innovation at risk," said PhRMA President and CEO John
J. Castellani. "As Bob Hugin assumes the chairmanship, I know he will continue
to emphasize the importance of patient-centered policies that properly value
medicines, incentivize innovation and provide a strong foundation for the
millions of U.S. jobs our industry creates and supports."

Mr. Hugin became CEO of Celgene Corporation in June of 2010 having served as
president and chief operating officer since May 2006. In June 2011, the
Celgene Board of Directors elected Mr. Hugin chairman. He was instrumental in
the strategic growth of the company, overseeing the expansion of Celgene from
a U.S.-based biopharmaceutical company to a global company with operations in
more than 50 countries located in the Americas, Europe, Japan and the
Asia-Pacific region. He joined Celgene as senior vice president and chief
financial officer in June 1999 and was elected to the Board of Directors in
December 2001.

"I look forward to working with our leadership team, the PhRMA staff, and our
member companies to advocate for policies that support the advancement of
medical innovation and that ensure access for patients to life-extending
therapies," Mr. Hugin said. "Through our actions, we must ensure that
continued medical innovation is part of the solution to healthcare costs and
economic growth in the long term."

Mr. Read is the chairman and CEO of Pfizer. He began his career with Pfizer in
1978 as an operational auditor. Mr. Read worked in Latin America through 1995,
holding positions in a number of Pfizer's international operations. In 1996,
he was appointed president of Pfizer's International Pharmaceuticals Group,
with responsibility for Latin America and Canada. He became executive vice
president, Europe in 2000, and was named a corporate vice president in 2001.
In 2006, he became senior vice president, Pfizer, and group president of the
Worldwide Biopharmaceutical Businesses.

"The biopharmaceutical industry's efforts to discover and develop innovative
new medicines not only has a significant impact in saving and improving lives,
but is also an essential driver of the broader economy," Mr. Read said. "PhRMA
is committed to working with policymakers, elected officials and our members
to develop the right policy framework that supports innovation that results in
creating value for society by enhancing productivity and improving the quality
of life globally."

Mr. Frazier is chairman, president and CEO of Merck & Co. Previously, he
served as president of Merck with responsibility for the company's three major
divisions: Global Human Health, Merck's sales and marketing division for
pharmaceutical and vaccine products; Merck Manufacturing, the company's
manufacturing and supply division; and Merck Research Laboratories, Merck's
research organization. Mr. Frazier received his bachelor's degree from The
Pennsylvania State University and holds a J.D. from Harvard Law School.

"Congratulations to my colleagues who have made many outstanding contributions
to healthcare and our industry through their work with PhRMA. I look forward
to continuing my work with PhRMA to ensure that patients and caregivers
benefit from the many scientific advances that the pharmaceutical industry has
to offer," said Mr. Frazier.

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents
the country's leading innovative biopharmaceutical research and biotechnology
companies, which are devoted to discovering and developing medicines that
enable patients to live longer, healthier, and more productive lives. Since
2000, PhRMA member companies have invested approximately $550 billion in the
search for new treatments and cures, including an estimated $48.5 billion in
2012 alone.

Find PhRMA Online:

  oWebsite – http://www.phrma.org 
  oFacebook – www.facebook.com/PhRMA 
  oBlog – www.phrma.org/catalyst 
  oTwitter – www.Twitter.com/PhRMA and www.Twitter.com/PhRMApress
  oYouTube – www.youtube.com/PhRMApress 

For information on how innovative medicines save lives, visit:

For information on the Partnership for Prescription Assistance, visit:

For information on ensuring the flow of medicines during public health
emergencies, visit http://www.rxresponse.org

SOURCE Pharmaceutical Research and Manufacturers of America

Website: http://www.phrma.org
Press spacebar to pause and continue. Press esc to stop.